Mama's Creations (NASDAQ:MAMA) Bolsa

Mama`s Creations

Mama's Creations

Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.

Mama's Creations Inc

WIIM

Redwire shares are trading higher after the company announced it will advance lunar and martian manufacturing technology after receiving a NASA critical design review pass.

<ul>
<li>US$50 million from an existing equity financing agreement.</li>
<li>US$50 million secured through a new institutional commitment from a strategic funding partner.</li>
</ul>
&nbsp;

News

Treasure Global Launches $100M Digital Asset Treasury Strategy To Reinforce Digital Infrastructure And Support Launch Of AI-Powered Consumer Intelligence Platform

<ul>
<li>New 8-count bottles now available through major retail pharmacies</li>
<li>ARAKODA&#xAE; is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria</li>
</ul>
WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=vgk--PA0N21vNZZm2YUhkUU5CxfJSet2QN6inrIBdQCrG4FYbfHZekx7do7x22oI0hYcjJnEKkBpOOne8FBy_FD5lem3FD0DvJeltwqs8vSBh7jI9WZnZCUGwLasNq8MDvPjxUIHQEN_8AKTPqWYV3662fF7pmk0U9_j-vdzQ5tMXwCE4SEeZt67dhN3DxJORV241dnG7shjujI3lwFk7ih7fjMEf7aUODXc8TSPkSqp3632qN0XDNcZ0gGg956mr1kgdjaCeLrErCId83TmGqJw5fcWxD02yd7jBr_f9xF8wWuhhzYbIHTZNhf3oYJJurnjq-QlQreJ5gykvngF3Q==">60 Degrees Pharmaceuticals, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>, SXTPW))) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the introduction of a new 8-count bottle format for ARAKODA&#xAE; (tafenoquine). The 8-count bottle format may be suitable for use with patients who are making shorter trips to areas of the world where malaria is endemic.
The new format expands the packaging options available to healthcare professionals who prescribe ARAKODA for the prevention of malaria and travelers taking trips of one week or less. The 8-count bottles are now available through major retail pharmacies, including Amazon Pharmacy.
For individuals traveling to endemic areas, ARAKODA tablets are indicated for the prophylaxis of malaria in patients 18 years of age and older. ARAKODA is the only weekly prophylactic therapy to provide protection against all stages of malaria.

Biotech

General

SXTP

60 Degrees Pharmaceuticals Launches New 8-Count Bottle Format Of ARAKODA

Counterpoint Research has cut growth expectations for <a href="https://www.benzinga.com/topic/smartphones" target="_blank" rel="noreferrer noopener">global smartphone shipments</a> in 2025 to 1.9% on Wednesday, down from 4.2% previously, citing Trump administration tariff-related uncertainties.
The firm also revised shipment growth from China down to near flat and expects Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>)&nbsp;shipments to slow as the companies pass the <a target="_blank" href="https://www.counterpointresearch.com/report/market-monitor-smartphone-brand-shipment-analysis-by-model-q1-2025" rel="noreferrer noopener">cost burden on</a> consumers.
President Trump announced a series of tariffs on its trading partners on April 2 to encourage manufacturing in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44796659/apple-tops-global-smartphone-sales-with-19-share-boosted-by-iphone-16e-emerging-market-growth" rel="noreferrer noopener">Apple Tops Global Smartphone Sales With 19% Share, Boosted By iPhone 16e, Emerging Market Growth</a>
On May 12, Beijing and Washington&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45676270/chinese-stocks-soar-as-us-court-blocks-trump-tariffs" rel="noreferrer noopener">agreed to lower&nbsp;tariffs</a> on each other's products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China's 125% duties on U.S. goods will drop to 10% for 90 days.
Last week, International Data Corporation (IDC) in its research report cut the 2025 <a href="https://www.benzinga.com/news/25/05/45708416/apple-iphone-shipment-could-decline-in-2025-as-tariff-competition-play-spoil-sport-idc" target="_blank" rel="noreferrer noopener">global smartphone shipment</a> growth outlook to 0.6% from 2.3%.
IDC expects China smartphone shipments to grow by 3% in 2025, driven by government subsidies.
In contrast,&nbsp;Apple&nbsp;is forecast to decline 1.9% in 2025 due to ongoing competition from&nbsp;Huawei, the overall economic slowdown, and the lack of subsidies for most of its models.
IDC expects the U.S. smartphone shipment to grow 1.9% in 2025, down from 3.3% in 2017, due to increased uncertainty and tariff-related price increases.
Meanwhile, Deepwater Research&#8217;s Gene Munster estimated that Apple has <a href="https://www.benzinga.com/markets/tech/25/06/45764870/apple-has-at-least-two-years-before-losing-customers-despite-its-several-ai-missteps-says-gene-munster-heres-why" target="_blank" rel="noreferrer noopener">about two years</a> to perfect its AI strategy, but it will require increased investments.
The AI features of smartphones are the<a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44613270/apple-set-for-strong-iphone-upgrade-cycle-driven-by-ai-analyst-says" rel="noreferrer noopener"> key deciding factor</a> determining their prospects.
<h2 class="wp-block-heading">Apple Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Apple have an average 1-year price target of $238.79, representing an expected upside of 17.47%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 3 analysts have bearish recommendations on Apple, while 21 analysts have bullish ratings. The street high price target from Wedbush is $325.0, while the street low from Jefferies is $167.88.
APPL&nbsp;Price Action:&nbsp;Apple stock is down 0.50% to $202.26 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45756083/which-internet-software-stocks-is-jp-morgan-bullish-on" target="_blank" rel="noreferrer noopener">Which Internet Software Stocks Is JP Morgan Bullish On?</a></li>
</ul>
Image by Wongsakorn 2468 via Shutterstock

Tech

Trading Ideas

AAPL

SSNLF

Tariffs, AI And Trade War: Apple's Smartphone Growth To Take A Hit, Experts Say

FUFU

BitFuFu shares are trading higher after the company provided monthly Bitcoin holdings and production updates for May.

Swedish biopharmaceutical company Camurus AB entered a collaboration and license agreement with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Tuesday.
Camurus granted Eli Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-acting incretin</a> products for cardiometabolic health based on Camurus&#8217; FluidCrystal technology.
The agreement <a target="_blank" href="https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/" rel="noreferrer noopener">comprises</a> up to four Lilly proprietary drug compounds, selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon, and GLP-1 receptor agonists, and an option to include amylin receptor agonists.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound Shows Superior Weight Loss Over Novo Nordisk&#8217;s Wegovy In Head-To-Head Trial</a>
Camurus' FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods – from days to months – with a single injection using a prefilled syringe or autoinjector pen.
Upon contact with bodily fluids in the tissue, the lipid solution transforms into a liquid crystalline gel that quickly and effectively encapsulates the active ingredient. The drug is slowly released as the liquid crystalline matrix gradually degrades in the tissue.
The technology is commercially and regulatory validated by market approvals and product sales in Europe, the US, and Australia.
In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to&nbsp;$290 million&nbsp;in upfront, development, and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single-digit royalties on global net product sales.
In May, Eli Lilly agreed to acquire&nbsp;SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45629147/breaking-the-pain-barrier-lillys-acquisition-of-siteone-aims-for-opioid-alternatives" rel="noreferrer noopener">hyperexcitability disorders</a>.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being&nbsp;studied for pain.
STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
In May, Eli Lilly entered into a strategic global research collaboration and licensing agreement with Rznomics Inc., a South Korea-based biopharmaceutical company specializing <a href="https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact" target="_blank" rel="noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics&#8217; proprietary trans-splicing ribozyme platform.
The collaboration&nbsp;<a target="_blank" href="https://www.prnewswire.com/news-releases/rznomics-enters-global-licensing-agreement-with-eli-lilly-for-rna-editing-therapeutics-302456852.html?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">focuses</a>&nbsp;on discovering and developing RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
Price Action: At the last check on Wednesday, LLY stock was up 0.40% at $753.80 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45767454/autoliv-boosts-shareholder-returns-with-21-dividend-hike-new-2-5-billion-buyback-program" target="_blank" rel="noreferrer noopener">Autoliv Boosts Shareholder Returns With 21% Dividend Hike, New $2.5 Billion Buyback Program</a></li>
</ul>
Photo: Shutterstock

Health Care

Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and maintains $24 price target.

Price Target

Analyst Ratings

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Maintains $24 Price Target

REVG

REV Group shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance.

Competitive statewide RFP win provides a platform for efficient expansion within the state
TEL AVIV, Israel, June 4, 2025 /PRNewswire/ -- SuperCom (NASDAQ:&nbsp;SPCB),&nbsp;a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has been awarded a statewide technology procurement contract by the North Carolina Sheriff's Association, emerging as the only new electronic monitoring technology provider selected through this competitive RFP. This contract serves as a procurement vehicle to allow all counties in North Carolina to contract directly with SuperCom on preset terms, most of the time without an additional RFP process. This strategic win is another testament to the Company's rapid expansion across the North American public safety market.

Contracts

SPCB

SuperCom Wins Statewide Technology Procurement Contract With North Carolina Sheriff's Association As Sole New Electronic Monitoring Provider

YEXT

Yext shares are trading higher after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.

Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and maintains $24 price target.

SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Maintains $24 Price Target

JFIN

Jiayin Group shares are trading higher after the company reported a year-over-year increase in its Q1 financial results.

Keybanc analyst Bradley Thomas reiterates Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Overweight and maintains $135 price target.

Reiteration

OLLI

Keybanc Reiterates Overweight on Ollie's Bargain Outlet, Maintains $135 Price Target

Thor Industries shares are trading higher after the company reported better-than-expected Q3 financial results.

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and maintains $95 price target.

DLTR

Telsey Advisory Group Maintains Market Perform on Dollar Tree, Maintains $95 Price Target

Keybanc analyst Bradley Thomas reiterates Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from Sector Weight to Sector Weight.

Keybanc Reiterates Sector Weight on Dollar Generalto Sector Weight

MRUS

Merus shares are trading lower following its $300 million public offering announcement.

LITE

Lumentum Holdings shares are trading higher after the company raised its Q4 guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.

UBS analyst Karl Keirstead upgrades Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Buy and raises the price target from $210 to $265.

Upgrades

SNOW

UBS Upgrades Snowflake to Buy, Raises Price Target to $265

ASAN

Asana shares are trading lower after the company issued FY26 guidance below estimates.

Press Releases

Mama's Creations Reports Third Quarter Fiscal 2025 Financial Results

Mama's Creations to Participate in Upcoming Investor Conferences

Mama's Creations to Host Virtual Investor Day Presentation on Wednesday, February 12, 2025

Mama's Creations to Present at Upcoming Investor Conferences

Mama's Creations to Host Fourth Quarter and Fiscal 2025 Earnings Call on April 8 at 4:30 p.m. Eastern Time

Mama's Creations Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Mama's Creations Invited to Attend Upcoming Investor Conferences

Mama's Creations to Host First Quarter Fiscal 2026 Earnings Call on June 3 at 4:30 p.m. Eastern Time

Mama's Creations to Showcase Expanded One-Stop-Shop Product Lineup at IDDBA 2025

Comments

Mama's Creations

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL